新闻BenzingaMoleculin Biotech Completes Patient Enrollment In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia Moleculin Biotech Completes Patient Enrollment In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia Benzinga 2026.09.29 12:47 (GMT+0) 在Benzinga上打开 其他新闻 布兰迪万房地产信托第三季度FFO为0.14美元,与预期一致;销售额1.25638亿美元,超过预估的1.21617亿美元 Meta将发行无投票权C类股,股东每持1股获派1股 Meta第三季度营收646亿美元,同比增长26% 美股三大指数集体收涨:SPCX上涨7.64%,Strategy(MSTR)上涨7.62% Anthropic推出主动式AI助手Claude Duet研究预览版 数据:Pump.fun向交易所转入12.98万枚SOL